ClinicalTrials.Veeva

Menu

Clinical Study for Safety and Acute Performance Evaluation of the THERMOCOOL SMARTTOUCH® SF-5D System Used With Fast Ablation Mode in Treatment of Patients With Paroxysmal Atrial Fibrillation. (QDOT-FAST)

Biosense Webster logo

Biosense Webster

Status

Completed

Conditions

Paroxysmal Atrial Fibrillation

Treatments

Device: THERMOCOOL SMARTTOUCH SF-5D Catheter

Study type

Interventional

Funder types

Industry

Identifiers

NCT03459196
BWI_2017_02

Details and patient eligibility

About

The QDOT-FAST study is a prospective, multi-center, non-randomized, interventional clinical study.

Full description

The purpose of this study is to evaluate safety and acute performance of the THERMOCOOL SMARTTOUCH® SF-5D catheter used in combination with the nMARQ™ Multi-Channel RF Generator with TGA mode in the treatment of Paroxysmal Atrial Fibrillation (PAF) during standard electrophysiology mapping and RF ablation procedures.

The QDOT-FAST study is a prospective, multi-center, non-randomized, interventional clinical study.

Enrollment

54 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age 18 or older.
  2. Signed the Patient Informed Consent Form (ICF).
  3. Diagnosed with symptomatic PAF
  4. Selected for catheter ablation through pulmonary vein isolation.
  5. Able and willing to comply with all pre-, post-, and follow-up testing and requirements (e.g. patient not confined by a court ruling).

Exclusion criteria

  1. Atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.
  2. Previous surgical or catheter ablation for atrial fibrillation.
  3. Previously diagnosed with persistent, longstanding AF and/or continuous AF >7 days, or >48 hrs. terminated by cardioversion.
  4. Documented Left Atrial thrombus on baseline/pre-procedure imaging.
  5. Any carotid stenting or endarterectomy.
  6. Left atrial (LA) size >50mm.
  7. Left Ventricular ejection fraction (LVEF) <40%.
  8. Uncontrolled heart failure or New York Heart Association (NYHA) function class III or IV.
  9. History of blood clotting or bleeding abnormalities
  10. Contraindication to anticoagulation
  11. History of a documented thromboembolic event (including transient ischemic attack (TIA)) within the past 12 months.
  12. Previous percutaneous coronary intervention (PCI) or myocardial Infarction (MI) within the past 2 months.
  13. Coronary artery bypass grafting (CABG) in conjunction with valvular surgery, cardiac surgery (e.g. ventriculotomy, atriotomy) or valvular cardiac (surgical or percutaneous) procedure.
  14. Rheumatic Heart Disease
  15. Awaiting cardiac transplantation or other cardiac surgery within the next 12 months.
  16. Unstable angina.
  17. Significant pulmonary disease (e.g. restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other diseaseor malfunction of the lungs or respiratory system that produces chronic symptoms.
  18. Acute illness, active systemic infection, or sepsis.
  19. Presence of atrial myxoma, interatrial baffle or patch
  20. Presence of intramural thrombus, tumor or other abnormality that precludes catheter introduction or manipulation.
  21. Presence of a condition that precludes vascular access.
  22. Presence of implanted pacemaker or implantable cardioverter-defibrillator (ICD).
  23. Presence of IVC filter
  24. Significant congenital anomaly or a medical problem that in the opinion of the investigator would preclude enrollment in this trial.
  25. Currently enrolled in an investigational study evaluating another device, biologic, or drug.
  26. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of child bearing age and plan on becoming pregnant during the course of the clinical investigation.
  27. Life expectancy or other disease processes likely to limit survival to less than 12 months.
  28. Presenting contra-indication for the devices used in the study, as indicated in the respective instructions for use.
  29. Categorized as vulnerable population and requires special treatment with respect to safeguards of well-being
  30. Contraindication to use of contrast agents for MRI such as advanced renal disease, etc. (at PI discretion)
  31. Presence of iron-containing metal fragments in the body
  32. Unresolved pre-existing neurological deficit.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

54 participants in 1 patient group

Treatment Group
Experimental group
Description:
A novel radiofrequency ablation catheter combining microelectrodes, thermocouples, porous tip irrigation and contact force sensing nMARQ Multi-Channel RF Generator with Software including TGA mode (Temperature Guided Ablation).
Treatment:
Device: THERMOCOOL SMARTTOUCH SF-5D Catheter

Trial documents
2

Trial contacts and locations

7

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems